Reuters (9/27, Clarke), the AP (9/27) and the Wall Street Journal (9/27) reported on Friday that the Food and Drug Administration issued a warning that tigecycline (Tygacil), Pfizer Inc’s antibacterial drug, can increase the risk of death when used as authorized by the FDA or for other non-approved conditions. A boxed warning will be added to the drug’s label, and the FDA indicated the drug should be used only in situations where no other treatment options are available.
The drug is approved to treat complicated skin and abdominal infections and community-acquired bacterial pneumonia. It is not approved to treat diabetic foot infection or hospital-acquired pneumonia.
Zoll, Kranz & Borgess, LLC (“ZKB”) specializes in assisting individuals injured or killed from dangerous, defective or contaminated medical drugs and devices. For more information, contact our pharmaceutical drug and device litigation attorneys by calling toll-free 888-841-9623.